Modulation of inflammatory paw oedema by cysteamine in the rat

Pharmacological Research

Volumn 45, Issue 4, 2002, Pages 275-284

  Abdel Salam, Omar M E ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Carrageenan; Cysteamine; Inflammation; Paw oedema

Indexed keywords

CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FORMALDEHYDE; HISTAMINE; INDOMETACIN; MERCAPTAMINE; SOMATOSTATIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EDEMA; INFLAMMATION; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; TISSUE LEVEL;

EID: 0036443753     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2002.0955     Document Type: Article

References (50)

1. Gillies G. Somatostatin: The neuroendocrine story. Trends Pharmacol Sci 1997; 18: 87-95.
2. Corsi MM, Ticozzi C, Netti C, Fulgenzi A, Tiengo M, Gaja G, Guidobono F, Ferrero ME. The effect of somatostatin on experimental inflammation in rats. Anesth Analg 1997; 85: 1112-5.
3. Green PG, Basbaum AI, Levine JD. Sensory neuropeptide interactions in the production of plasma extravasation in the rat. Neuroscience 1992; 50: 745-9.
4. Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93: 2000-6.
5. Helyes Z, Pinter E, Szolcsanyi J, Horvath J. Anti-inflammatory and antinociceptive effect of different somatostatin-analogs. Neurobiology (Bp) 1996; 4: 115-7.
6. Bjorling DE, Saban MR, Saban R. Effect of octreotide, a somatostatin analogue, on release of inflammatory mediators from isolated guinea pig bladder. J Urol 1997; 158: 258-64.
7. Carlton SM, Du J, Zhou S, Coggeshall RE. Tonic control of peripheral cutaneous nociceptors by somatostatin receptors. J Neurosci 2001; 21: 4042-9.
8. Carlton SM, Du J, Davidson E, Zhou S, Coggeshall RE. Somatostatin receptors on peripheral primary afferent terminals: Inhibition of sensitized nociceptors. Pain 2001; 90: 233-44.
9. Szolcsanyi J, Pinter E, Helyes Z, Oroszi G, Nemeth J. Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. Br J Pharmacol 1998; 125: 916-22.
10. Szolcsanyi J, Helyes Z, Oroszi G, Nemeth J, Pinter E. Release of somatostatin and its role in the mediation of the anti-inflammatory effect induced by antidromic stimulation of sensory fibres of rat sciatic nerve. Br J Pharmacol 1998; 123: 936-42.
11. Ohno H, Kuraishi Y, Nanayama T, Minami M, Kawamura M, Satoh M. Somatostatin is increased in the dorsal root ganglia of adjuvant-inflamed rat. Neurosci Res 1990; 8: 179-88.
12. Ohno H, Kuraishi Y, Minami M, Satoh M. Modality-specific antinociception produced by intrathecal injection of anti-somatostatin antiserum in rats. Brain Res 1988; 474: 197-200.
13. Traub RJ, Brozoski D. Anti-somatostatin antisera but neither a somatostatin agonist (octreotide) nor antagonist (CYCAM) attenuates hyperalgesia in the rat. Peptides 1996; 17: 769-73.
14. Szabo S, Reichlin S. Somatostatin in rat tissues is depleted by cysteamine administration. Endocrinology 1981; 109: 2255-7.
15. Vecsei L, Ekman R, Alling C, Widerlov E. Influence of cysteamine and cysteine on open-field behaviour, and on brain concentrations of catecholamines, somatostatin, neuropeptide Y, and corticotropin releasing hormone in the rat. J Neural Transm Gen Sect 1989; 78: 209-20.
16. Sagar SM, Laundry D, Millard WJ, Badger TM, Arnold MA, Martin JB. Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine. J Neurosci 1982; 2: 225-60.
17. Webb SM, Champney TH, Steger RW, Vaughan MK, Reiter RJ. Cysteamine effects on somatostatin, catecholamines, pineal NAT and melatonin in rats. Brain Res Bull 1986; 16: 315-20.
18. Szabo S, Reichlin S, Bollinger-Gruber JA, Brown A. Somatostatin depleting potency of cysteamine-related thiols and amines in the rat: Structure-activity relation. J Pharmacol Exp Ther 1992; 263: 752-6.
19. Widmann R, Maas D, Sperk G. Effect of local injection of cysteamine and cystamine on somatostatin and neuropeptide Y levels in the rat striatum. J Neurochem 1988; 50: 1682-6.
20. Haroutunian V, Mantin R, Campbell GA, Tsuboyama GK, Davis KL. Cysteamine-induced depletion of central somatostatin-like immunoactivity: Effects on behavior learning memory and brain neurochemistry. Brain Res 1987; 403: 234-42.
21. Fitzgerald LW, Dokla CP. Morris water task impairment and hypoactivity following cysteamine-induced reductions of somatostatin-like immunoreactivity. Brain Res 1989; 505: 246-50.
22. Ohno M, Shibata S, Yamamoto T, Watanabe S. Working memory deficits following muscarinic blockade combined with depletion of brain somatostatin in rats. Brain Res 1993; 610: 348-53.
23. Srikant CB, Patel YC. Cysteamine-induced depletion of brain somatostatin is associated with up-regulation of cerebrocortical somatostatin receptors. Endocrinology 1984; 115: 990-5.
24. Dalsgaard CJ, Vincent SR, Hokfelt T, Wiesenfeld-Hallin Z, Gustafsson L, Elde R, Dockray GJ. Effects of cysteamine on pain behaviour and on somatostatin- and substance P-like immunoreactivity in the substantia gelatinosa of the rat. Eur J Pharmacol 1984; 104: 295-301.
25. McIntosh CH, Bakich V, Bokenfohr K, DiScala-Guenot D, Kwok YN, Brown JC. Cysteamine-induced reduction in gastrointestinal somatostatin: Evidence for a region-specific loss in immunoreactivity. Regul Pept 1988; 21: 205-18.
26. Mantin R, Campbell GA, Tsuboyama GK, Davis KL. Cysteamine-induced depletion of central somatostatin-like immunoactivity: Effects on behavior, learning, memory and brain neurochemistry. Brain Res 1987; 403: 234-42.
27. Schettini G, Florio T, Magri G, Grimaldi M, Meucci O, Landolfi E, Marino A. Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin. Eur J Pharmacol 1988; 151: 399-407.
28. Pieretti S, Di Giannuario A, Capasso A, Sorrentino L, Loizzo A. Effects induced by cysteamine on chemically-induced nociception in mice. Life Sci 1994; 54: 1091-9.
29. Bryant HU, Holaday JW, Bernton EW. Cysteamine produces dose-related bidirectional immunomodulatory effects in mice. J Pharmacol Exp Ther 1989; 249: 424-9.
30. Karalis K, Mastorakos G, Sano H, Wilder RL, Chrousos GP. Somatostatin may participate in the antiinflammatory actions of glucocorticoids. Endocrinology 1995; 136: 4133-8.
31. Winter CA, Risley EA, Nuss GW. Carrageenan-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med 1962; 111: 544-52.
32. Vinegar R, Truax JF, Selph JL. Quantitative comparison of the analgesic and anti-inflammatory activities of aspirin, phenacetin and acetaminophen in rodents. Eur J Pharmacol 1976; 37: 23-30.
33. Obukowicz MG, Welsch DJ, Salsgiver WJ, Martin-Berger CL, Chinn KS, Duffin KL, Raz A, Needleman P. Novel, Selective 6 or 5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. J Pharmacol Exp Ther 1998; 287: 157-66.
34. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999; 96: 10403-8.
35. Penning TD et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of SC-58635 (celecoxib). J Med Chem 1997; 40: 1347-65.
36. Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 1998; 30: 5-11.
37. Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A. Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther 1994; 269: 7-14.
38. Ohkubo T, Shibata M, Takahashi H, Inoki R. Roles of substance P and somatostatin on transmission of nociceptive information induced by formalin in spinal cord. J Pharmacol Exp Ther 1990; 252: 1261-8.
39. Aguila MC, McCann SM. Stimulation of somatostatin release from median eminence tissue incubated in vitro by taurine and related amino acids. Endocrinology 1985; 116: 1158-62.
40. Bakhit C, Koda L, Benoit R, Morrison JH, Bloom FE. Evidence for selective release of somatostatin-14 and somatostatin-28(1-12) from rat hypothalamus. J Neurosci 1984; 4: 411-9.
41. William YZ, Connor JD. Differential effects of octreotide on motor responses to nicotine in rats. Pharmacol Biochem Behav 1992; 43: 1165-8.
42. Catania A, Arnold J, Macaluso A, Hiltz ME, Lipton JM. Inhibition of acute inflammation in the periphery by central action of salicylates. Proc Natl Acad Sci USA 1991; 88: 8544-7.
43. Ceriani G, Macaluso A, Catania A, Lipton JM. Central neurogenic antiinflammatory action of alpha-MSH: Modulation of peripheral inflammation induced by cytokines and other mediators of inflammation. Neuroendocrinology 1994; 59: 138-43.
44. Delfs JR, Dichter MA. Effects of somatostatin on mammalian cortical neurons in culture: Physiological actions and unusual dose response characteristics. J Neurosci 1983; 3: 1176-88.
45. Bakhit C, Swerdlow N. Behavioural changes following central injection of cysteamine in rats. Brain Res 1986; 365: 159-63.
46. Millard WJ, Sagar SM, Landis DMD, Margin JB. Cysteamine: A potent and specific depletor of pitutary prolactin. Science 1982; 217: 452-5.
47. Abdel-Salam O, Szolcsanyi J, Mozsik G. Differences in action of topical and systemic cysteamine on gastric blood flow, gastric acid secretion and gastric ulceration in the rat. J Physiol (Paris) 1996; 90: 63-73.
48. Wei E, Thomas HA. Anti-inflammatory peptide agonists. Ann Rev Pharmacol Toxicol 1993; 33: 91-108.
49. Vane JR. Prostaglandins as mediators of inflammation. Adv Prostaglandin Thromboxane Res 1976; 2: 791-801.
50. Voilley N, de Weille J, Mamet J, Lazdunski M. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci 2001; 21: 8026-33.